Inmune Bio (INMB) Research & Development (2018 - 2026)
Inmune Bio (INMB) posted Research & Development of $3.6 million for Q1 2026, up 56.33% sequentially from $2.3 million in Q4 2025, and down 52.34% YoY from $7.6 million in Q1 2025.
Inmune Bio (INMB) Research & Development (2018 - 2026) Analysis & Trends
Inmune Bio has reported Research & Development for 9 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Research & Development fell 52.34% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (down 48.12% YoY) and the FY2025 annual result came in at $20.7 million, down 37.71% from the prior year.
- Research & Development grew to $3.6 million in Q1 2026 per INMB's latest filing, from $2.3 million in the prior quarter.
- Over five years, Research & Development peaked at $10.1 million in Q3 2024 and troughed at $2.3 million in Q4 2025.
- A 5-year average of $5.6 million and a median of $5.2 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 110.33% in 2024, then sank 68.33% in 2025.
- Over 5 years, Research & Development stood at $3.4 million in 2022, then surged by 76.16% to $6.0 million in 2023, then grew by 22.41% to $7.4 million in 2024, then tumbled by 68.33% to $2.3 million in 2025, then soared by 56.33% to $3.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.6 million, $2.3 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 97.90 Mn |
| 10 | Inmune Bio | 61.19 Mn | 42.77 Mn | - | -803,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -803,000.00 |
| Mar 31, 2026 | 3.64 Mn |
| Dec 31, 2025 | 2.33 Mn |
| Sep 30, 2025 | 4.89 Mn |
| Jun 30, 2025 | 5.80 Mn |
| Mar 31, 2025 | 7.64 Mn |
| Dec 31, 2024 | 7.35 Mn |
| Sep 30, 2024 | 10.07 Mn |
| Jun 30, 2024 | 7.05 Mn |
| Mar 31, 2024 | 8.69 Mn |
| Dec 31, 2023 | 6.01 Mn |
| Sep 30, 2023 | 5.99 Mn |
| Jun 30, 2023 | 4.15 Mn |
| Mar 31, 2023 | 4.13 Mn |
| Dec 31, 2022 | 3.41 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 4.19 Mn |
| Mar 31, 2022 | 4.31 Mn |
| Dec 31, 2021 | 7.07 Mn |
| Sep 30, 2021 | 6.52 Mn |